PLAU and prostate carcinoma: PKD3 together with PKD2 initiate prostate cancer cell migration by modulating urokinase-type plasminogen activator (uPA) expression and activation in a nuclear factor kappa B (NF-κB) and histone deacetylase 1 (HDAC1)-mediated manner [15].